Historic

- Creation of Stallergenes by the Institut Mérieux, a world leader in vaccines

- Stallergenes enters the Benelux and North African markets.

- Stallergenes markets products in Germany

- Stallergenes develops and supplies one of the first anti-allergies vaccines to be administered orally.

- First NPP* automated production chain implemented by Stallergenes

- Merger of Stallergenes with the Allergen Division - Institut Pasteur

- Expansion of Stallergenes in Greece, Spain, Portugal and Turkey

- Acquisition of Stallergenes by Wendel Investissement

- Launch of Staloral^® (allergen immunotherapy by sublingual delivery)

- Creation of a subsidiary in Germany and purchase of a laboratory in Belgium

- Creation of a subsidiary in Italy and in Central Europe (Czech Republic and Slovakia)

- Introduction of Stallergenes to the Second Market of the Paris Stock Exchange

- With the purchase of DHS, the allergy division of Bayer Pharma, the Stallergenes-DHS Group becomes the world's number 2 company in its sector

- Opening of a subsidiary in Spain

- Awarded international ISO 9001 certification

- Pursuit of international development in South Africa, Australia, New Zealand and Poland.

- Stallergenes enters the Middle East markets

- Launch of Staloral 300^® (desensitisation therapy via sublingual drops) in Europe

- Initiation of the first clinical study comparing the efficacy of a recombinant allergen tablet to a current product.

- Launch of a clinical study on the Grasses sublingual tablet, which represents a new therapeutic class and a significant advance for patients

- Acquisition of IPI's desensitization activity in Spain and Portugal

- Success of the clinical study on the Grasses tablet

- Subsidiary formation for promotional activity in the Czech Republic and in Slovakia

- Positive results from the first Proof of concept clinical study comparing the efficacy of a recombinant allergen (Bet v 1) with the current product based on a natural birch pollen extract.

- Results of the Phase I safety study of the Mites desensitisation tablet.

- Signature of an agreement for development and distribution of the desensitisation tablet with the Canadian company, Paladin Labs >>See the press release

- Development of a first product candidate as part of the Enhanced Allergens program with a view to pharmaceutical and preclinical development.

- Creation of a subsidiary in the Netherlands in partnership with the Dutch company SANMED B.V >> See the press release

- Commitment to the development and production of recombinant birch pollen and dust mites allergens (Partnerships with CMC and Protein'Expert)

- Positive results for the phase III clinical study of grass pollen induced rhino-conjuctivitis in children (sublingual desensitisation tablet)

- Start of two clinical studies : a phase II/III for mite induced allergic rhinitis in adults (mites tablet) in Europe ; a phase III for mite induced allergic asthma in adults (sublingual desensitisation drops treatment)

- Finalization of the construction of the new industrial unit on the Antony's site.

- Achievement of the market authorization of the sublingual desensitisation tablet Oralair^® in Germany, serving as the reference country as part of the European mutual recognition procedure See the press release

 -Obtaining of market authorization in Gernany for Oralair® ,sublingual grass pollen desensitization tablet, for adult use.

-Extremely positive clinical results in a pharmacodynamic study carried out in an allergen challenge chamber with Oralair® (V056.07).

- Inauguration of a new pharmaceutical unit for the production of allergens on the  site (Paris region).

-Partnership with Catalent and The Medical House for the European marketing of an adrenalin auto-injector (Adreflex®)

-Launch of a phase IIb/III trial in Europe for the treatment of allergic rhinoconjunctivitis induced by birch pollen in adults, with a tablet containing the major recombinant allergen for this pollen, r Bet v 1 (V059.08).

-Launch of a phase III clinica trial in the  United States with Oralair® for the treatment of allergic rhinoconjunctivitis induced by grass pollen in adults (V061.08).

-Launch of a new phase III in Europe with Oralair® for grass-induced rhinoconjunctivitis in adults and adolescents in an optimised protocol (V060.08)           

- Obtaining of a paediatric marketing authorization in Germany for Oralair®.

-Creation of two new subsidiaries in Switzerland and Austria

-Signing of a partnership with Boryung for the promotion and distribution of Stallergenes products in Korea.

-Signing of a partnership with Solvay Pharmaceuticals for the promotion and distribution of Stallergenes products in Russia and in the Commonwealth of Indepedent States (CIS)

- Ares Life Sciences (a health care investment firm) acquired in November Wendel’s equity interest in Stallergenes.  The investment company owns 73% of the share capital and voting rights of the pharmaceutical company.